EHA 2022 | The safety and efficacy of ibrutinib for the treatment of CLL
Paul Hampel
• 10 Jun 2022
Paul Hampel, MD, Mayo Clinic, Rochester, MN, talks on the safety and efficacy of the covalent Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib for the treatment of chronic lymphocytic leukemia (CLL). Both long-term follow up data, for instance the E1912 trial (NCT02048813), and confirmatory Phase III studies demonstrate the benefits of ibrutinib over current gold-standard chemoimmunotherapy regimens. Dr Hampel comments on the toxicities and challenges following administration of ibrutinib, and how these issues may be overcome. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
